Drug Trial Radar · NCT06275893
IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy
Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1
Actual
Start
Mar 29, 2024
Primary completion
Aug 15, 2025
Study completion Apr 15, 2026
Sponsor
- Lead sponsor
- Implicit BioscienceIndustry
- Sponsor type
- Industry
- First posted
- Feb 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test IC14 (atibuclimab) in patients with arrhythmogenic cardiomyopathy (ACM) and who have an implantable cardoverter/defibrillator in place. ACM is also called arrhythmogenic right ventricular dysplasia (ARV) or arrhythmogenic right ventricular cardiomyopathy (ARVC). The main questions the study aims to answer are the effect of treatment on blood markers of inflammation, safety, and pharmacokinetics. There will also be measurements of myocardial imaging of C-C chemokine receptor type 2 (CCR2+) immune cells (optional), monitoring of cardiac arrhythmias using the patient's pre-existing intracardiac cardioverter/defibrillator (ICD) and a Holter monitor, electrocardiogram (ECG), echocardiogram (ECHO), and blood tests. Results will be compared to baseline; there is no inactive placebo treatment group. Participants will be asked to undergo screening and baseline testing, then receive 4 intravenous infusions with blood measurements before and after the infusion (including 24, 48, and 72 hours and 7, 14, and 28 days). Participants will be offered specialized scanning of the heart muscle, and will be asked to provide recordings from their ICD, undergo Holter monitoring twice, and have electrocardiograms (ECG), echocardiograms (ECHO) and blood tests.
Conditions
- Arrhythmogenic Right Ventricular Dysplasia
- Arrhythmogenic Left Ventricular Cardiomyopathy
- Arrhythmogenic Right Ventricular Cardiomyopathy 1
- Arrhythmogenic Cardiomyopathy
- ACM
- ARVC
- PKP2
Interventions
IC14Biological
recombinant monoclonal antibody directed against cluster of differentiation 14 (CD14) antigen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Treatment-emergent adverse events and serious adverse eventsTime frame: Baseline through 14 weeks
- Safety: Incidence of anti-drug antibodiesTime frame: Baseline, 4 weeks, and 14 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Washington University School of Medicine
St Louis, Missouri
Cleveland Clinic
Cleveland, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.